Coulter Partners announces top hires for VC & PE portfolio companies Q1-2023

Search Highlights

Recent top global hires for Venture Capital and Private Equity portfolio companies, covering a broad range of disciplines and sectors across Life Sciences, Health, and Tech.

This quarter’s successful placements include:

• CEO, Diagnostics (UK)
• CEO, Oncology biotech (Italy)
• Chief Business Officer, Infectious diseases (Canada)
• Chief Development Officer, Biologics (Netherlands)
• Chief Business Officer, AI monitoring devices (France)
• Chief Research & Development Officer, Contract research organization (Canada)
• Country Manager UK, Telehealth (Norway)
• SVP Research, Ultrasound devices (US)
• VP, Antibody Engineering & Protein Sciences, Drug discovery services (US)
• Head of Translational Medicine, Cell therapies (Switzerland)
• Global Director Medical Affairs, Plasma derived therapeutics (US)
• Sales Director, Digital imaging (Germany)
• Board Director (US), Immuno-oncology (France)
• Partner Digital Health Investments, Life science investor (Italy)

Newly opened projects include:

• CEO, AI-enabled precision medicines (France)
• Chief Medical Officer, Antibody-drug conjugates (ADCs) (Denmark)
• Chief Business Officer, Cell and gene therapies (UK)
• Head of Regulatory & Quality Affairs, Imaging biomarkers (UK)
• Global Head of Marketing, Natural ingredients and food tech (Denmark)
• VP Business Development, Antibody therapeutics (US)
• VP Corporate Development, Radiopharmaceuticals (China)
• VP People, Cardiac devices (France)
• VP Clinical Affairs, Analgesics (US)
• Country Managing Director, Veterinary services (Belgium)
• Chair, Medical devices (US)
• Board Director (Clinical), Gene therapy (UK)